World Market for G-Protein-Coupled Receptors (GPCRs) Targeting Drugs to Reach US$120.5 Billion By 2017, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on the ‘G-Protein-Coupled-Receptors (GPCRs)’ market. Global market for G-Protein-Coupled Receptors (GPCRs) is projected to reach US$120.5 billion by the year 2017. Major factors driving growth in the market include rising interest among researchers for GPCR drug targets, increased know-how of membrane structures of GPCR, and advancements in identification as well as crystallization of newer structures. In addition to these, emergence of efficient and powerful technologies used in GPCR screening is expected to stimulate market growth.

Follow us on LinkedIn – G-protein-coupled receptors (GPCRs) represent signal-transducing molecules that transmit signals to cells. They play a key role in converting extracellular stimulus into intracellular responses, and are therefore responsible for all physiological processes. Dysfunctional GPCRs are the prime cause for a host of human diseases, both physiological and pathophysiological, ranging from allergies, depression to hypertension. Given the fact that G-protein is a stimulative hormone receptor, which influences the activity of intracellular metabolism, studying the mechanisms by which hormone receptors dictate the function of complex tissues will provide invaluable input in developing drugs that will efficiently target the disease condition. Newer research studies have revealed that this super family of signal transducing molecules is capable of sending extraneous signals into the cell through alternate pathways, such as, Jak2 kinase, and protein kinase C. Consequently, GPCR emerges as one of the most powerful drug target classes.

Significant untapped potential exists for pharmaceutical development based on GPCRs. Drugs targeting GPCR have superior therapeutic benefits, as they are more active at cell surface receptors. Almost half of pharmaceutical drugs available in the market target GPCRs, which corroborates the potential these targets have in the area of medicine. The GPCR family of receptors flaunts the potential to provide optimum therapeutic benefits in a wide range of diseases, such as, hypertension, allergic rhinitis, schizophrenia, and pain, among numerous others. Recent research and advancements in medicinal chemistry, structure-based drug designing, and screening methodologies opened a plethora of opportunities for the GPCR industry, leading to further exploitation of this target class. Currently, R&D efforts are being directed at known as well as orphan GPCRs, which show significant potential for the development of new GPCR targeting therapeutics.

Currently over 250 GPCRs have been identified together with their endogenous ligand. Conversely, there still exists over 150 GPCRs for which endogenous ligand has not been identified till date, making these orphan GPCRs a potential laden area for therapeutic targets. The newly isolated orphan receptors exhibit massive potential in pioneering drug development and discovery. Orphan GPCRs are therefore forecast to emerge into a core focus area for pharmaceutical companies and academic researchers in the upcoming years. Hitherto a neglected area of opportunities, “deorphanizing” the currently orphan GPCRs is poised to become the new name of the game, as scientists embark on this largely uncharted path of revelation and discovery. PathHunter Arrestin technology recently developed by DiscoveRx increases the chances of successful de-orphanization of orphan GPCRs, which over the last few years witnessed a steady decline. Some of the evolving concepts that are likely to aid in dealing with the challenging GPCR-based drug discovery environment as well as in identifying new mechanisms for validated targets include GPCR allosterism, GPCR dimerisation, and GPCR oligomerisation.

Major players profiled in the report include 7TM Pharma A/S, Actelion Pharmaceuticals Ltd., Acure Pharma AB, Arena Pharmaceuticals, Inc., Addex Pharmaceuticals, Acadia Pharmaceuticals Inc., DiscoveRx Corporation, Dimerix Bioscience Pty Ltd, Euroscreen SA, and Trevena, Inc. among others.

The research report titled “G-Protein-Coupled Receptors (GPCRs): A Global Market Report” announced by Global Industry Analysts, Inc., provides comprehensive market overview, trends & issues, recent industry activity and profiles of market players worldwide. The report offers analytics pertaining to sales of drugs targeting G-Protein-Coupled Receptors for the global market for years 2009 through 2017. The study also provides historic data for an insight into market evolution over the period 2003 through 2008.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/G_Protein_Coupled_Receptors_GPCRs_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/
####

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website